• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Nanobac Pharmaceuticals Completes Phase I Scientific Plan

Posted on: Wednesday, 15 August 2007, 09:12 CDT

Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) ("Nanobac" or "the Company") announces that it has completed Phase I of its 2006 scientific plan advancing Nanobac's claim that Calcifying Nano Particles (CNPs) are pathogens. Concurrent results from scientific research conducted at the Mayo Clinic, NASA Johnson Space Center, University of California at San Francisco, and Shantou University Medical Center demonstrate that CNPs can induce inflammation, calcification and thrombosis. Disease states such as atherosclerosis (cardiovascular disease) and stone forming diseases such as Kidney Stones, Gall Stones and Prostate Stones are all associated with CNPs. The results of studies concerning self replication and Koch's postulates are currently being analyzed. The results of the studies will be detailed in subsequent releases.

Data from the completed studies confirm that Nanobac's proprietary diagnostics specifically detect CNPs. The data further suggests that specific drug therapies can be created to treat CNPs and that the course of treatment can be monitored by Nanobac's proprietary diagnostics.

"We streamlined the R & D process to specifically focus on initiatives which we believe are the quickest path for products to market," commented Dr. Benedict Maniscalco, Nanobac's Co-Chairman and Chief Medical Officer, "and we are very excited about the completed work of our collaborative partners which allows the Company to transition to product development."

For more information on the Company's direction please refer to the Investor Section at www.nanobac.com. Further, for frequent updates on Nanobac's progress please register as a friend of Nanobac at www.nanobac.com.

Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. For more information, visit our website at: http://www.nanobac.com.

Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes,""anticipates,""intends,""plans,""expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals Inc. has no specific intention to update these statements.

Source: Business Wire

More News in this Category